Key result
Female patients with symptomatic obstructive HCM initiated on mavacamten were older and more likely to have functional class III symptoms than males.
Why the study?
Little is known about sex differences in characteristics and treatment outcomes among patients initiated on mavacamten in the post-approval, real-world phase.
Are there sex differences in baseline characteristics among patients with symptomatic obstructive HCM initiated on mavacamten?
Cohort (n=96)
No
Are there sex differences in baseline characteristics among patients with symptomatic obstructive HCM initiated on mavacamten?
In a real-world cohort of patients with obstructive HCM initiated on mavacamten, females were older, had more severe symptoms and higher LVOT gradients, and were more likely to live alone compared to males.
Answers are grounded in this paper and cite their sources.
Sex differences in real-world mavacamten response for obstructive HCM need confirmation; leaves open whether sex-stratified monitoring or dosing is warranted.
Background Mavacamten, a first-in-class cardiac myosin ATPase inhibitor was approved for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (HCM) in April 2022. Little is known about sex differences in characteristics and treatment outcomes among patients initiated on mavacamten in the post-approval, real-world phase. Methods Retrospective study of all patients who completed 36 weeks of mavacamten from May 2022 to December 2023 at a single center. Baseline demographics, clinical characteristics, and echocardiographic data, including left ventricular ejection fraction (LVEF) and left ventricular outflow tract (LVOT) gradients at rest and with Valsalva, were collected. Descriptive statistics were presented as means (standard deviation [SD]) or as counts and percentages as appropriate and stratified by sex. Results Ninety-six patients (54% female) were initiated on mavacamten. Females were started on mavacamten at a significantly older mean age (68 [13] vs. 57 [14] years, p<0.001) and were more severely symptomatic, as assessed by New York Heart Association (NYHA) class at baseline, prior to initiating mavacamten (56% female NYHA III vs. 23% male NYHA III, p=0.001). At the baseline echocardiogram, females had a higher mean resting LVOT gradient at rest (67 [45] vs. 43 [28] mm Hg, p=0.003) and with Valsalva (89 [36] vs. 66 [24] mm Hg, p<0.001). Females were less likely to have a care partner (71% vs. 95%, p=0.002) and more likely to live alone (29% vs. 7%, p=0.013). Conclusion In this large single center real world study of patients with symptomatic obstructive HCM initiated on mavacamten, females were older at HCM diagnosis and suffered from worse symptoms compared with men, similar to the findings of the EXPLORER-HCM trial. We also found that females in this cohort were less likely to have a care partner and more likely to live alone, highlighting an opportunity to structure care interventions that may improve health status and the treatment experience for females.
No takes yet. Share an insight, caveat, or question.
Duqueney et al. (2025) conducted a cohort in Symptomatic obstructive hypertrophic cardiomyopathy (n=96). Female sex vs. Male sex was evaluated on NYHA class III at baseline (p=0.001). Female patients with symptomatic obstructive HCM initiated on mavacamten were older and more likely to have functional class III symptoms than males.
Synapse has enriched 10 related papers. Consider them for comparative context: